These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 24943301)
1. Potential peptides in atherosclerosis therapy. Marleau S; Mellal K; Huynh DN; Ong H Front Horm Res; 2014; 43():93-106. PubMed ID: 24943301 [TBL] [Abstract][Full Text] [Related]
2. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. Urban D; Pöss J; Böhm M; Laufs U J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703 [TBL] [Abstract][Full Text] [Related]
7. Understanding PCSK9 and anti-PCSK9 therapies. McKenney JM J Clin Lipidol; 2015; 9(2):170-86. PubMed ID: 25911073 [TBL] [Abstract][Full Text] [Related]
8. [News in lipid lowering treatment]. Vrablík M; Češka R Vnitr Lek; 2014 Nov; 60(11):949-57. PubMed ID: 25600041 [TBL] [Abstract][Full Text] [Related]
9. New Therapies in the Treatment of High Cholesterol: An Argument to Return to Goal-Based Lipid Guidelines. Shrank WH; Barlow JF; Brennan TA JAMA; 2015 Oct; 314(14):1443-4. PubMed ID: 26258765 [No Abstract] [Full Text] [Related]
10. [Clinical significance of and treatment options for increased lipoprotein(a)]. Zsíros N; Paragh G; Harangi M Orv Hetil; 2014 Apr; 155(16):607-14. PubMed ID: 24733102 [TBL] [Abstract][Full Text] [Related]
11. PCSK9: is it fluoride for cardiology? King SB JACC Cardiovasc Interv; 2014 Nov; 7(11):1331-2. PubMed ID: 25459045 [No Abstract] [Full Text] [Related]
12. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients. Costet P; Hoffmann MM; Cariou B; Guyomarc'h Delasalle B; Konrad T; Winkler K Atherosclerosis; 2010 Sep; 212(1):246-51. PubMed ID: 20619837 [TBL] [Abstract][Full Text] [Related]
13. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Sahebkar A; Watts GF Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia. Stawowy P; Just IA; Kaschina E Coron Artery Dis; 2014 Jun; 25(4):353-9. PubMed ID: 24667128 [TBL] [Abstract][Full Text] [Related]
17. [PCSK9 inhibitors and dyslipidemias: an update on clinical evidence]. Norata GD G Ital Cardiol (Rome); 2014 May; 15(5):301-5. PubMed ID: 25002170 [TBL] [Abstract][Full Text] [Related]
18. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Schwartz GG; Bessac L; Berdan LG; Bhatt DL; Bittner V; Diaz R; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Mahaffey KW; Moryusef A; Pordy R; Roe MT; Rorick T; Sasiela WJ; Shirodaria C; Szarek M; Tamby JF; Tricoci P; White H; Zeiher A; Steg PG Am Heart J; 2014 Nov; 168(5):682-9. PubMed ID: 25440796 [TBL] [Abstract][Full Text] [Related]
19. Highlights of the 83rd European Atherosclerosis Society (EAS) annual Congress, Glasgow 22-25 March, 2015. Stock J Atherosclerosis; 2015 Sep; 242(1):45-7. PubMed ID: 26177273 [No Abstract] [Full Text] [Related]
20. The role of PCSK9 in intestinal lipoprotein metabolism: synergism of statin and ezetimibe. Fazio S Atheroscler Suppl; 2015 Feb; 17():23-6. PubMed ID: 25659873 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]